The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.
Outside of Humira revenue declines, AbbVie reported that both Skyrizi and Rinvoq experienced exceptional growth, with global revenues increasing 50.4% and 55.1% over the same period.